Thus, genes specifically upregulated in the presence of progestin in cells expressing SUMO-deficient PR are among the same genes highly over-expressed (top 5% to 10%) in ERBB2-positive breast cancers (Figure 5A, Additional file 4 Table s1, shaded rows). This evidence concerns the gene ERBB2 and breast cancer.